Potential treatment paradigms for anxiety disorders

Bibliography

• LANG PJ: Appraisal of systematic desensitization techniques with children and adults. II: Process and mechanisms of change, theoretical analysis and implications for treatment and clinical research. In : Assessment, and States of the Behavior Therapies and Associ-ated Developments. Franks CM (Ed.), McGraw Hill, New York (1968).
   Google Scholar
• STAHL SM: Amdolytics and sedative-hypnotics. In: Essential Psychopharmacology : Neuroscientific Basis and Clinical Applications. Cambridge University Press (1999) 7:167–215.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and statistical manual of mental disorders (4th edn) (DSM-IV). Washington, DC (1994): APA.
   Google Scholar
• WITTCHEN HU, ZHAO S, KESSLER RC et al.: DSM III-R generalized anxiety disorder in the national comorbidity survey. Arch. Gen. Psychiatry (1994), 51:355–64.
   PubMed Web of Science ®Google Scholar
• MAGEE WJ, EATON WW, WITTCHEN HU et al.:Agoraphobia, simple phobia and social phobia in the National Comorbidity Survey. Arch. Gen. Psychiatry (1996) 53:159–168.
   PubMed Web of Science ®Google Scholar
• DURHAM RC, MURPHY T, ALLAN T et al. Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder. Br. J. Psychiatry (1994) 165:315–323.
   PubMed Web of Science ®Google Scholar
• GOULD RA, OTTO MW, POLACK MH, YAP L: Cognitivebehavioral and pharmacological treatment of general-ised anxiety disorder: a preliminary meta-analysis. Behav. Ther. (1997) 28:285–305.
   Web of Science ®Google Scholar
• WOODS JH, KATZ JL, WINGER G:. Benzodiazepines: use,abuse, and consequences. Pharmacol. Rev. (1992) 44:151–347.
   Google Scholar
• KAPLAN HI, SADOCK BJ : Anxiety disorders. In: ConciseTextbook of Clinical Psychiatry derived from : Kaplan and Sadock's synopsis of psychiatry/ Harold I Kaplan, Benjamin J Sadock, Jack A Grebb (7 th ed). (1994):189–217.
   Google Scholar
• BAYLE FJ: Comment prescrire les medicaments del'anxiété. L 'Encéphale (1998) XXIX:272–279.
   Google Scholar
• FERRERI M, HANTOUCHE EG, BILLARDON M: Intérêt de l'hydroxyzine dans le trouble anxiété généralisée: etude control& en double aveugle versus placebo. L 'Encéphale (1994) 20(6):785–791.
   PubMedGoogle Scholar
• LADER MH: A comparison of hydroxyzine, buspirone and placebo in patients with generalised anxiety. Biol. Psychiatry (1997) 42(1S):297.
   Google Scholar
• HASKINS in BAKISH D: The patient with comorbid depression and anxiety: The unmet need. J. Clin. Psychiatry (1999) 60(6):20–24.
   Google Scholar
• SHEEHAN DV: How treatable are anxiety disorders? American Psychiatric Association Congress Washington, DC, USA (1999).
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Practice guideline for the treatment of patients with panic disorder. Am. J. Psychiatry (1998) 155 (5):1–34.
   Web of Science ®Google Scholar
• BANDELOW B: The assessment of efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int. Clin. Psychophar-macol. (1995) 10:73–82.
   PubMed Web of Science ®Google Scholar
• BOYER W: Serotonin uptake inhibitors are superior toimipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int. Clin. Psychopharmacol (1995) 10:45–49.
   PubMed Web of Science ®Google Scholar
• CROSS NATIONAL COLLABORATIVE PANIC STUDY: Second phase investigators drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo. Br. J. Psychiatry (1992) 160:191–192.
   PubMed Web of Science ®Google Scholar
• MARKS I, GREIST J, BASOGLU M et al.: Comment on the second phase of the Cross-National Collaborative Panic Study. Br. J. Psychiatry (1992) 160 :202–205.
   Web of Science ®Google Scholar
• MILLET BJ, BAYLE FJ, OLIE JP: Prospects for amdolytic therapy: a reflection from different view points. Drugs Discov. Today (1998) 3(10): 471–479.
   Web of Science ®Google Scholar
• ANDREWS G, CRINO R, HUNT C et al: In: The Treatment ofAnxiety Disorders. Clinician's Guide at Patient Manuals. Cambridge, Cambridge University Press (1994):13–56.
   Google Scholar
• BARLOW DH, LEHMAN CL: Advances in the psychoso- cial treatment of anxiety disorders: implication for national health care. Arch. Gen. Psychiatry (1996) 53:727–735.
   PubMed Web of Science ®Google Scholar
• PELISSOLO A, LEPINE JP: Psychopharmacological approaches to the treatment of anxiety disorders: a critical review and practical guidelines. In: Clinical management of Anxiety. Den Boer JA (Ed.), Marcel Dekker, New-York (1997):249–294.
   Google Scholar
• LIEBOWITZ R, SCHNEIER F, CAMPEAS R etal.: Phenelzine versus atenolol in social phobia. Arch. Gen. Psychiatry (1992) 49:290–300.
   PubMed Web of Science ®Google Scholar
• BALDWIN D, BOBES J, STEIN DJ et al: Paroxetine in social phobia/ social anxiety disorder: Randomised, double-blind, placebo-controlled study. Br. J. Psychiatry (1999) 175:120–126.
   PubMed Web of Science ®Google Scholar
• KELSEY JE: Venlafaxine in social phobia. Psychophar-macol. Bull. (1995) 31:767–761.
   PubMed Web of Science ®Google Scholar
• MILLET BJ: Troubles obsessionnels-compulsifs. In: Phobies et Obsessions. André C (Ed.), Doin Initiatives Santé, Paris (1998):137–180.
   Google Scholar
• GRIEST JH, JEFFERSON JW, KOBAK KA eta].: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch. Gen. Psychiatry (1995) 52:53–60.
   Google Scholar
• NUTT D, BELL C: Practical pharmacotherapy for anxiety. Adv. Psychiatric Treat. (1997) 3:79–85.
   Google Scholar
• SHADER RI, GREENBLATT DJ: The Pharmacotherapy of Acute Anxiety: a mini up-date. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds.) Raven Press, New-York (1995) 113:1341–1348.
   Google Scholar
• BALLENGER JC, McDONALD S, NOYES R eta].: The first double-blind, Placebo-Controlled Trial of a Partial Benzodiazepine Agonist Abecarnil (ZK 112–119) in Generalized Anxiety Disorder. Psychopharmacol (1991) 27(2):171–179.
   Google Scholar
• MORSELLI PL: On the therapeutic action of alpidem in anxiety disorders: an overview of European data. Pharmacopsychiatty (1990) 23 (Supp1.2):129–135.
   Google Scholar
• BRAD WEJN J, KOSZYCKI D, COUETOUX DU TERTRE A et al.: The panicogenic effects of cholecystokinin-tetrapeptid are antagonized by L-365, 260 a central cholecystokinin receptor antagonist in patients with panic disorder. Arch. Gen. Psychiatry (1994) 51:486–493.
   Google Scholar
• VAN VLIET IM, WESTENBERG HGM, SLAAP BR, DEN BOER JA, HO PIAN KL: Amdogenic effects of pentagastrin with social phobia and healthy controls. Biol. Psychiatry (1997) 42:76–78.
   PubMed Web of Science ®Google Scholar
• HENDRIE CA, DOURISH CT: Amdolytic profile of the cholecystin antagonist devazepide in mice. Br. J. Pharmacol. (1990) 99 (Suppl.):138.
   Google Scholar
• BOUGEROL T, LANCON C, LLORCA PM: Les amdolytiques. Encycl. Med. Chir. (1997) 37 (860E5):178.
   Google Scholar
• FERRERI M, ALBI JM: Neurotic inhibition and transnoso-graphic approach. With regard to a multicentric study with carpipramine. L'Encéphale (1987) 13(6): 357–365.
   Google Scholar
• BRESSA GM, MARINI S, GREGORI S: Serotonin S2 receptors blockade and generalized anxiety disorders/ A double bind study of ritanserin and lorazepam. Int. J. Clin. Pharmacol. Res. (1987) 7:111–9.
   PubMedGoogle Scholar
• KATZ RJ, LANDAU PS, LOTT M et al.: Serotonergic (5-11T2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder. Biol. Psychiatry (1993) 34:41–44.
   PubMed Web of Science ®Google Scholar
• LADER MH: Ondansetron in the treatment of anxiety. Satellite symposium at the 5th World Congress of Biological Psychiatry. Florence, Italy (1990:16–19.
   Google Scholar
• LECRUBIER V, PUECH AJ, AZCONA et al.: A randomised double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (1993) 112:129–33.
   PubMed Web of Science ®Google Scholar
• GREENSHAW AJ, SILVERSTONE PH: The non-antiemetic uses of serotonin 5-11T3 receptor antagonists. Drugs (1997) 53(0:20–39.
   PubMed Web of Science ®Google Scholar
• SHADER RI, GREENBLATT DJ: Use of benzodiazepines in anxiety disorders. New Engl. J. Med. (1993) 328:1398–1405.
   PubMed Web of Science ®Google Scholar
• EISEN JL, PHILLIPS KA, BAER L eta].: The Brown Assess-ment of Beliefs Scale : reliability and validity. Am. J. Psychiatry (1998) 155:102–108.
   Google Scholar
• GELFIN Y, GORFINE M, LERER B: Effect of clinical doses of fluoxetine on psychological variables on healthy volunteers. Am. J. Psychiatry (1998) 155:290–292.
   PubMed Web of Science ®Google Scholar
• KNUTSON B, WOLKOWITZ OM, COLE SW eta].: Selective alteration of personality and social behavior by serotoninergic interventions. Am. J. Psychiatry (1998) 155:373–379.
   Google Scholar
• EKSELIUS L, VON KNORRING L: Changes in persoanlity traits during treatment with sertraline or citalopram. Br. J. Psychiatry (1999) 174:444–448.
   PubMed Web of Science ®Google Scholar
• JUDD LL, KESSLER RC, PAULUS AP et al.: Comorbidity as a fundamental feature of generalized anxiety disorder: results from the national Comorbidity Study (NCS). Acta Psychiatr. Scand. Suppl. (1998) 398:6–11.
   Google Scholar
• WORLD HEALTH ORGANIZATION : The ICD-10 Classifi-cation of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization (1992).
   Google Scholar